Pharmaceutical News and Articles

Repatha Now Indicated for Adults at Increased Risk for Major Adverse Cardiovascular Events Due to Uncontrolled LDL-C

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune, Inc. (Nasdaq ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, toda

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine Ixchiq In the U.S.

Saint Herblain (France), August 25, 2025 Valneva SE (Nasdaq VALN Euronext Paris VLA), a specialty vaccine company, today announced that the United States Food a

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

NEWARK, CA ACCESS Newswire August 25, 2025 Protagonist Therapeutics, Inc. ( Protagonist or the Company ) announced today that rusfertide, a potential first-in-c

Stealth Biotherapeutics Announces FDA Acceptance of Elamipretide NDA Resubmission

Mississippi Declares Public Health Emergency Over Infant Deaths

MONDAY, Aug. 25, 2025 Mississippi has declared a public health emergency after reporting its highest infant death rate in more than a decade. In 2024, the state

Over 32,000 Pounds of Meat Recalled Over False USDA Inspection Labels

MONDAY, Aug. 25, 2025 More than 32,000 pounds of meat are being recalled nationwide because they were sold with a false USDA mark of inspection, federal officia

NYC Legionnaires' Outbreak: 6 Deaths, 112 Cases

MONDAY, Aug. 25, 2025 New York City health officials confirmed a sixth death linked to a Legionnaires disease outbreak in Harlem where 112 people have now been

Omega-3 PUFA Intake May Be Protective Against Myopia

Omega-3 polyunsaturated fatty acid ( -3 PUFA) intake may be protective against myopia in children, according to a study published online Aug. 19 in the British

29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season

Overall, 29 percent of infants born during October 2023 to March 2024 were immunized against respiratory syncytial virus (RSV) during the 2023 to 2024 respirato